Caricamento...
Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies for Hemophilia A Patients
A major complication in treating hemophilia A is the development of neutralizing antibodies (inhibitors) against therapeutic administered factor VIII (FVIII), which occurs in approximately 20-30% of patients with severe disease. These inhibitors render FVIII replacement therapy ineffective and incre...
Salvato in:
| Pubblicato in: | Int J Mol Cell Med |
|---|---|
| Autori principali: | , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Babol University of Medical Sciences
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7422849/ https://ncbi.nlm.nih.gov/pubmed/32832483 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.22088/IJMCM.BUMS.9.1.33 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|